PixarBio NeuroRelease A Non-Addictive, Non-Opiate Morphine Replacement™

Introduction from CSO Frank Reynolds

Knee Surgery Pain Treatment

Shoulder Surgery Pain Treatments

Hip Surgery Pain Treatments

Back Pain – Facet Joint

Non-Opiate Post-Operative, Acute & Chronic Pain System

One year after hip, knee and spine surgeries, 80% of patients report that pain is moderate to severe after surgery. Pain limits the patient’s physical therapy outcome and thereby reduces the possibility of a full recovery.

NanoMedicines and Microparticles

Nanoscale Delivery Systems and Microparticles provide new biomaterials platform opportunities for targeted drug delivery. PixarBio is using patent pending formulations of FDA approved biomaterials and FDA approved non-opiate drugs to target key neurological areas to treat pain.

PixarBio cofounder Frank Reynolds has an in-depth knowledge of the needs of the postsurgical pain, acute pain and chronic pain markets. Frank’s passion for delivering improved quality of life for all neurological patients drives PixarBio’s commitment to concurrently engineer new treatments for a wide range of painful conditions. We believe that these treatments may reduce drug addiction associated with opiate pain killers and improve clinical outcomes.

Our founders’ expertise in cGMP manufacturing of biomaterials with extensive safety records and a history of FDA regulatory approvals has given PixarBio the insight in-house on how to reach those goals by applying our core competencies to developing new treatment options for doctors and patients.

With our team’s expertise on over 60 products approved by the FDA to start human studies, we have unmatched experience in the drug delivery system space and a track record of successfully developing FDA approved products.